These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22192819)

  • 1. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
    Lee AJ; Swanton C
    Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From genomic landscapes to personalized cancer management-is there a roadmap?
    Swanton C; Caldas C
    Ann N Y Acad Sci; 2010 Oct; 1210():34-44. PubMed ID: 20973797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance.
    Lee AJ; Kolesnick R; Swanton C
    Expert Rev Mol Med; 2009 May; 11():e15. PubMed ID: 19467173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogenomics approaches to novel target discovery.
    Gaither LA
    Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
    Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
    Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
    Smith L; Lind MJ; Welham KJ; Cawkwell L;
    Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges.
    Horswell S; Matthews N; Swanton C
    Cancer Lett; 2013 Nov; 340(2):220-6. PubMed ID: 23142290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.
    Tan DS; Gerlinger M; Teh BT; Swanton C
    Eur J Cancer; 2010 Aug; 46(12):2166-77. PubMed ID: 20413300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer.
    Mullenders J; Bernards R
    Oncogene; 2009 Dec; 28(50):4409-20. PubMed ID: 19767776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability.
    Guenot D; Guérin E; Aguillon-Romain S; Pencreach E; Schneider A; Neuville A; Chenard MP; Duluc I; Du Manoir S; Brigand C; Oudet P; Kedinger M; Gaub MP
    J Pathol; 2006 Apr; 208(5):643-52. PubMed ID: 16450341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge of intratumour heterogeneity in precision medicine.
    Seoane J; De Mattos-Arruda L
    J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress towards personalized medicine.
    Bates S
    Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
    Arnedos M; Vielh P; Soria JC; Andre F
    J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.